Results for Metabolic Disease

1 - 10 of 193

Dr. John studies metabolism in the setting of pediatric infections, in order to identify new anti-infective drug targets, understand drug resistance, and develop new diagnostics.

E-mail:

johna3 [at] chop.edu

Marni J. Falk, MD

Dr. Falk is a Clinical Geneticist who serves as executive director of the Mitochondrial Medicine Frontier Program. Her translational research lab investigates the causes and global metabolic consequences of mitochondrial disease, as well as targeted therapies, in C. elegans, zebrafish, mouse, and human tissue models of genetic-based respiratory chain dysfunction.

E-mail:

falkm [at] chop.edu

Will Bailis, PhD

Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.

E-mail:

bailisw [at] chop.edu

Andrew Edmondson, MD, PhD

Dr. Edmondson is an attending physician with the Metabolic Disease Program and the Division of Human Genetics at CHOP, and an assistant professor of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania. His research focuses on the study of glycosylation in the brain.

E-mail:

edmondsona [at] chop.edu

Itzhak Nissim, PhD

Dr. Nissim is a biochemist and a pioneer in the application of stable isotopes, mass spectrometry, and nuclear magnetic resonance to study metabolome and fluxome and their coupling to genome in normal and disease states. His long-standing interest focuses on understanding the cause, mechanisms, and outcome of metabolic disorders.

E-mail:

nissim [at] chop.edu

Michelle Denburg, MD, MSCE

Dr. Denburg addresses fundamental limitations in understanding of skeletal morbidity in patients with chronic kidney disease, glomerular disease, and urinary stone disease, and develops resources to conduct observational research and trials to optimize health outcomes in these high risk populations.

E-mail:

denburgm [at] chop.edu

Can Ficicioglu, MD, PhD

E-mail:

ficicioglu [at] chop.edu

Andrew C. Calabria, MD

Dr. Calabria is interested in the clinical evaluation of children at risk for bone disease. He has particular interest in metabolic bone disease/osteopenia of prematurity in at-risk neonates/infants.

E-mail:

calabriaac [at] chop.edu

Justin Berger, MD, PhD

Dr. Berger's research focus involves the development of pediatric heart failure and underlying metabolic drivers. He studies how improving metabolic dysregulation may also benefit cardiac dysfunction.

E-mail:

bergerj [at] chop.edu

Daniel P. Kelly, MD

Dr. Kelly’s research career began with deciphering the genetic basis of inborn errors in metabolism in children, followed by a series of breakthrough discoveries relevant to the diagnosis and treatment of common forms of heart failure in the general population.

E-mail:

dankelly [at] pennmedicine.upenn.edu